Erianin

Cas No.:	95041-90-0
SMILES:	OC1=CC(CCC2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC
Formula:	C18H22O5
M.Wt:	318.36
Purity:	>98%, Standard References Grade
Sotrage:	4°C for 1 year, -20°C for more than 2 years

Description:	Erianin, often used as an antipyretic and analgesic agent, could inhibit IDO-induced tumor angiogenesis.
In Vitro:	Erianin is often used as antipyretic and analgesic agent. Erianin belongs to bibenzyl derivatives in structure, with the activity of anti-virus, anti-bacterial, as well as anti-benign prostatic hyperplasia. Erianin has obvious damage on 2LL-IDO cells, Erianin basically has no cytotoxicity on human normal liver cell line L02, and cell viability is maintained at around 85%[1]. Erianin inhibits the growth of HeLa cells and induces apoptosis in a dose‑ and time‑dependent manner, inducing cell cycle arrest at the G2/M stage. Erianin treatment also increases the expression of Bax and caspase‑3, but decreases levels of Bcl‑2 and phosphorylated‑ERK1/2[2].
References:	[1]. Su C, et al. Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis. Biomed Pharmacother. 2017 Apr;88:521-528. [2]. Li M, et al. Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal-regulated kinase signaling pathway. Oncol Lett. 2018 Oct;16(4):5006-5012.